Opthea Limited (OPT)
Market Cap | 287.35M |
Revenue (ttm) | 385,275 |
Net Income (ttm) | -142.52M |
Shares Out | 150.76M |
EPS (ttm) | -1.72 |
PE Ratio | n/a |
Forward PE | 6.73 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 25,945 |
Open | 1.860 |
Previous Close | 1.910 |
Day's Range | 1.860 - 1.980 |
52-Week Range | 1.600 - 4.400 |
Beta | 0.70 |
Analysts | Strong Buy |
Price Target | 15.00 (+679.22%) |
Earnings Date | Aug 6, 2024 |
About OPT
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth fac... [Read more]
Financial Performance
In 2023, Opthea's revenue was 385,275, an increase of 93.60% compared to the previous year's 199,005. Losses were -142.52 million, 53.6% more than in 2022.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for OPT stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 679.22% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/q/g/press6-2485891.jpg)
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1) will close at 5:00 pm (Melbourne ...
![](https://cdn.snapi.dev/images/v1/e/x/press11-2479125.jpg)
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024
![](https://cdn.snapi.dev/images/v1/7/i/press5-2474766.jpg)
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
Financing extends Opthea's cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD
![](https://cdn.snapi.dev/images/v1/n/h/conf7-2458670.jpg)
Opthea To Present at Clinical Trials at the Summit Meeting
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
![](https://cdn.snapi.dev/images/v1/o/u/press10-2449538.jpg)
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expecte...
![](https://cdn.snapi.dev/images/v1/n/e/press5-2402414.jpg)
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapi...
![](https://cdn.snapi.dev/images/v1/o/x/conf2-2391162.jpg)
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
![](https://cdn.snapi.dev/images/v1/8/u/press16-2362084.jpg)
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
![](https://cdn.snapi.dev/images/v1/r/k/press7-2357768.jpg)
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
![](https://cdn.snapi.dev/images/v1/q/p/press11-2355436.jpg)
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leade...
![](https://cdn.snapi.dev/images/v1/e/c/press13-2330366.jpg)
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to tr...
![](https://cdn.snapi.dev/images/v1/d/r/press8-2309762.jpg)
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent...
![](https://cdn.snapi.dev/images/v1/c/f/press14-2299873.jpg)
Opthea Reports Half-Year Financial Results and Business Updates
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025
![](https://cdn.snapi.dev/images/v1/b/9/press14-2282651.jpg)
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation
![](https://cdn.snapi.dev/images/v1/i/p/press15-2275316.jpg)
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD
![](https://cdn.snapi.dev/images/v1/e/i/press9-2254821.jpg)
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseas...
![](https://cdn.snapi.dev/images/v1/t/8/press2-2208727.jpg)
Opthea to Receive US$35M Commitment and Additional US$50M Funding
MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/k/u/press7-2201442.jpg)
Opthea Receives A$8.8 million R&D Tax Incentive
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/m/z/conf20-2179314.jpg)
Opthea to Present at the FLORetina 2023 Congress
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/p/5/conf11-2149092.jpg)
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/w/v/conf9-2127373.jpg)
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/0/1/press8-2125133.jpg)
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors
![](https://cdn.snapi.dev/images/v1/l/j/press12-2085277.jpg)
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progre...
![](https://cdn.snapi.dev/images/v1/m/b/conf10-2052999.jpg)
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progr...
![](https://cdn.snapi.dev/images/v1/5/s/press13-2038991.jpg)
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
MELBOURNE, Australia, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (Opthea or the Company) (ASX:OPT; NASDAQ:OPT) is pleased to announce the successful completion of the institutional component of ...